港股异动 | 先声药业(02096)再涨超6% 上半年创新研发成果显着 预计达利雷生有望于年内正式上市

智通财经
Aug 25, 2025

智通财经APP获悉,先声药业(02096)再涨超6%,截至发稿,涨4.4%,报14.72港元,成交额2.1亿港元。

消息面上,近日,先声药业公布上半年业绩。交银国际指出,先声药业1H25业绩如期实现高增长,收入和经调整净利润同比分别增长15%/21%,符合该机构的预期,其中创新药相关收入增长26%,占总收入的比例同比提升6.6ppts至77.4%。该行指出,公司1H25整体研发投入超10亿元,占总收入比例接近30%,创新研发成果显着,包括:上市达利雷生和苏维西塔单抗;完成两单BD出海交易,分别与艾伯维和NextCure就GPRC5D/BCMA/CD3三抗和CDH6 ADC达成,其中前者有望于2026年完成I期爬坡后迎来合作伙伴正式行权。

中金认为,先声药业上半年业绩超出市场预期,主要是创新药业务带动。1H25公司创新药业务收入达到27.76亿元,同比提升26.0%,收入占比从2024年74.3%提升3.1ppt至77.4%,科赛拉、先比新舌下片等创新药快速放量,公司预计科唯可(达利雷生)有望2H25正式上市;同时公司三款产品(苏维西塔单抗、达利雷生、先比新舌下片)入选近期商保目录,该行认为有望带动创新药收入持续快速提升。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10